From Nasdaq: 2025-01-18 01:05:24

The FDA has approved AstraZeneca and Daiichi Sankyo’s Datroway for the treatment of unresectable or metastatic HR-positive, HER2-negative breast cancer. The approval was based on a Phase III trial showing a 37% reduction in disease progression or death compared to chemotherapy. Datroway is the eighth new medicine AstraZeneca plans to deliver by 2030. The drug is a TROP2-directed antibody drug conjugate jointly developed by AstraZeneca and Daiichi Sankyo. Regulatory submissions for Datroway in breast cancer are under review in the EU, China, and other regions.



Read more at Nasdaq: FDA Okays AstraZeneca And Daiichi’s Datroway For Metastatic HR-Positive, HER2-Negative Breast Cancer